Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Abstract Multiple studies highlight the strong prevalence of anti‐poly(ethylene glycol) (anti‐PEG) antibodies in the general human population. As we develop therapeutic modalities using this polymer, it is increasingly relevant to assess the importance of anti‐PEG antibodies on biological performances. Here, we show that the anti‐PEG Immunoglobulin M (IgM) raised in mice following the injection of polymeric nanoparticles could have significant neutralizing effects on subsequent doses of PEGylated nanosystems in vivo. The circulation times of PEGylated nanoparticles and liposomes were strongly reduced in animals with circulating anti‐PEG IgMs, irrespective of the PEG density or the surface properties of the system. In comparison, despite that anti‐PEG IgMs could bind free methoxy‐terminated PEG and PEGylated bovine serum albumin, the circulation kinetics of these systems remained unaltered in the presence of antibodies. The binding of IgMs to the PEGylated surface of nanoparticles alters the nature of the proteins adsorbed in the surrounding corona, notably due to the activation of the complement cascade. These changes are responsible for the observed differences in circulation times. In comparison, the PEG‐BSA is unable to activate complement, even in the presence of anti‐PEG IgMs. These results inform on how anti‐PEG antibodies can affect the fate of PEGylated nanomaterials and highlight how the architecture of nanoparticles impacts the deposition of the protein corona. Graphical abstract Figure. No Caption available. HighlightsIntravenous injection of long circulating, empty PEG‐PLGA nanoparticles induces the production of anti‐PEG IgMs in mice.Anti‐PEG IgMs impact the circulation of PEGylated nanoparticles and liposomes, but not free PEG and PEGylated proteins.Anti‐PEG IgMs increase complement activation and alter the biological pathways involved in the clearance of nanoparticles.Anti‐PEG IgMs bind to protein conjugates, but do not activate complement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
Walkey, C. D., Olsen, J. B., Guo, H., Emili, A., & Chan, W. C. W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja2084338 · Cited by 1,926 · cited 2×
“Surface functionalization of nanomaterials with PEG appears to increase the biocompatibility of nanoparticles prepared from metal [4], mesoporous silica [16], hydrophobic polymers [7] or lipids [8], as well as carbon nanotubes [17].”
BackgroundMonopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., & Dawson, K. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107583h · Cited by 1,835
Formulation of functionalized PLGA-PEG Nanoparticles for in vivo targeted drug delivery
Cheng, J., Teply, B. A., Sherifi, I., Sung, J., Luther, G., Gu, F. X., Levy-Nissenbaum, E., Radovic-Moreno, A. F., Langer, R., & Farokhzad, O. C. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.09.047 · Cited by 1,273
Schöttler, S., Becker, G., Winzen, S., Steinbach, T., Mohr, K., Landfester, K., Mailänder, V., & Wurm, F. R. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.330 · Cited by 1,272
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 9×
“This work used knockout animals to show that interactions of nanoparticles with apolipoproteins had a stronger effect on their blood circulation than interactions with the complement system [7].”
BackgroundMethodResultInfluentialSelf-citationArmstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
A Decade of the Protein Corona
Ke, P. C., Lin, S., Parak, W. J., Davis, T. P., & Caruso, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b08008 · Cited by 672 · cited 1×
“Understanding which proteins are involved in this corona and how they can alter the interactions of nanomaterials with living systems is an important prerogative to design more effective nanoparticles for biomedical applications [3].”
BackgroundAnti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
He, Q., Zhang, J., Shi, J., Zhu, Z., Zhang, L., Bu, W., Guo, L., & Chen, Y. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.10.046 · Cited by 502
Cited by
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Chen, B.-M., Cheng, T.-L., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 563
Shahbazi, M.-A., Faghfouri, L., Ferreira, M. P. A., Figueiredo, P., Maleki, H., Sefat, F., Hirvonen, J., & Santos, H. A. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00283a · Cited by 523
Rampado, R., Crotti, S., Caliceti, P., Pucciarelli, S., & Agostini, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00166 · Cited by 390
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Metadata
- Authors
- Grenier, P., Viana, I. M. D. O., Lima, E. M., & Bertrand, N.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 287
- Pages
- 121-131
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2888472260
- Cited by
- 127
- References
- 15
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo. https://app.cochat.ai/papers/10.1016/j.jconrel.2018.08.022
- The paper
- Grenier, P., Viana, I. M. D. O., Lima, E. M., & Bertrand, N. (2018). Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2018.08.022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.